The abstract is read at the publisher; the summary is JClub's.
Multi-omics-constrained near-genome-scale kinetic ensembles for BRCA1-mutant ovarian cancer cells identify 28 enzyme-mediated metabolic vulnerabilities, including 24 linked to DrugBank compounds.
- Why it matters: Time-resolved, system-wide effects of metabolic reprogramming in cancer are not well characterized, limiting mechanistic hypotheses and actionable vulnerability discovery.
- What they did: The study built uncertainty-quantified kinetic ensembles for isogenic BRCA1 wild-type versus BRCA1-mutant ovarian cancer cells covering over 2,100 reactions, then applied metabolic control analysis to nutrient, metabolite, and enzyme perturbations.
- The result: In silico inhibition of thymidylate synthase, hexokinase, and triokinase predicted target- and physiology-specific pathway rewiring and a shared ceramide-linked stress response, and mapped enzyme-activity shifts to BRCA1-associated transcription factors.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.